GleamWall
中文EN

MTRI InMed Pharmaceuticals Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1728328 · Fiscal year ends 06/30

Financial factors as of 2025-12-31 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-6.7%
TTM net income YoY3.1%
TTM EPS YoY76.7%
Revenue 3-yr CAGR40.8%
Net income 3-yr CAGR—

Margins

Gross margin29.7%
Operating margin—
Net margin-170.1%
FCF margin—
EBITDA margin—

Returns

ROE-97.2%
ROA-77.8%
ROIC (approx.)—
Asset turnover0.46x

Leverage & solvency

Liabilities / assets14.3%
Debt / equity0.00x
Current ratio5.94x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30
Income statement
Revenue—$4.94M
Cost of revenue—$3.24M
Gross profit—$1.71M
R&D expense$3.03M$2.82M
SG&A expense$6.66M$5.41M
Pretax income-$11.37M-$8.69M
Net income-$12.56M-$8.16M
EPS (basic)-3.12-8.36
EPS (diluted)-3.12-8.36
Weighted avg. shares (diluted)4.16M975,895
Balance sheet
Cash & equivalents$2.19M$10.74M
Short-term investments$39,670$43,384
Receivables—$465,104
Inventory—$961,173
Current assets$2.68M$12.87M
PP&E, net$221,037$992,199
Intangibles—$1.62M
Total assets$3.03M$15.58M
Current liabilities$1.96M$1.84M
Total liabilities$1.96M$2.15M
Shareholders' equity$1.08M$13.43M
Shares outstanding5.34M2.00M
Cash flow statement
Operating cash flow-$8.64M-$8.10M
Financing cash flow$94,496$12.27M
Depreciation & amortization$205,271$212,839
Stock-based compensation$106,866$119,307

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.